Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL6221914 | 0.90 | CYP2D6 (0.43) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL794596 | 0.82 | TNF (0.44) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL120501 | 0.80 | AHR (0.45) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL3961345 | 0.80 | TNF (0.42) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL30391792 | 0.80 | AHR (0.45) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL14909105 | 0.80 | TNF (0.57) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL1960195 | 0.80 | USP2 (0.45) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL1394068 | 0.80 | TNF (0.42) | AHRTNFRIPK1GPR84SLC6A2 | |
| SCHEMBL23658432 | 0.77 | AHR (0.47) | AHRTNFRIPK1GPR84NR3C1 | |
| SCHEMBL4484912 | 0.77 | AHR (0.47) | AHRTNFRIPK1GPR84AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4526426-A2 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | Danmarks Tekniske Universitet (DK) | 2025-03-26 | — | — | EP | claimed |
| WO-2023222879-A2 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-23 | — | — | WO | claimed |
| CN-114805664-B | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-114805664-A | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114292582-B | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114292582-A | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-104073045-A | Application of halogenated indole and derivatives thereof as marine antifouling agent | YANTAI INST COASTAL ZONE RES CAS | 2014-10-01 | — | — | CN | claimed |
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | UNIV DANMARKS TEKNISKE (DK) | 2025-11-20 | — | — | US | disclosed |
| EP-4608507-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | Neurocrine Biosciences, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2003016307-A1 | β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016276-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1173432-A1 | PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY | NPS Allelix Corp. (CA) | 2002-01-23 | — | — | EP | disclosed |
| US-6251893-B1 | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NPS ALLELIX CORP. (CA) | 2001-06-26 | — | — | US | disclosed |
| WO-2000063203-A1 | PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-10-26 | — | — | WO | disclosed |
| US-6133287-A | SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS, E.G., PSYCHOSIS, SCHIZOPHRENIA, MANIC DEPRESSION, DEPRESSION, MEMORY DISTURBANCES, PARKINSONISM, AMYLOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S AND HUNTINGTON'S DISEASE | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | AHR 3011/4885TNF 4685/4885RIPK1 1743/4885 |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | INMT, KARS1, MIA3 | AHR 361/4885TNF 4064/4885RIPK1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.